NASDAQ:GMAB Genmab A/S (GMAB) Stock Forecast, Price & News $36.08 -0.41 (-1.12%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$35.98▼$36.4250-Day Range$36.07▼$42.2552-Week Range$31.40▼$47.50Volume315,497 shsAverage Volume382,735 shsMarket Capitalization$23.83 billionP/E Ratio36.08Dividend YieldN/APrice Target$41.40 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Genmab A/S MarketRank™ ForecastAnalyst RatingHold2.27 Rating ScoreUpside/Downside14.7% Upside$41.40 Price TargetShort InterestHealthy0.44% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings Growth17.65%From $1.02 to $1.20 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.18 out of 5 starsMedical Sector137th out of 969 stocksPharmaceutical Preparations Industry42nd out of 440 stocks 3.1 Analyst's Opinion Consensus RatingGenmab A/S has received a consensus rating of Hold. The company's average rating score is 2.27, and is based on 6 buy ratings, 7 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $41.40, Genmab A/S has a forecasted upside of 14.7% from its current price of $36.08.Amount of Analyst CoverageGenmab A/S has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.44% of the outstanding shares of Genmab A/S have been sold short.Short Interest Ratio / Days to CoverGenmab A/S has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in Genmab A/S has recently decreased by 16.23%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldGenmab A/S does not currently pay a dividend.Dividend GrowthGenmab A/S does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GMAB. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 3 people have searched for GMAB on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Genmab A/S to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Genmab A/S insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.54% of the stock of Genmab A/S is held by insiders.Percentage Held by InstitutionsOnly 6.29% of the stock of Genmab A/S is held by institutions. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Genmab A/S are expected to grow by 17.65% in the coming year, from $1.02 to $1.20 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Genmab A/S is 36.08, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 117.12.Price to Earnings Ratio vs. SectorThe P/E ratio of Genmab A/S is 36.08, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 143.29.Price to Earnings Growth RatioGenmab A/S has a PEG Ratio of 2.17. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGenmab A/S has a P/B Ratio of 6.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Genmab A/S (NASDAQ:GMAB) StockGenmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company also develops Teclistamab, which is in Phase 2 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.Read More GMAB Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GMAB Stock News HeadlinesSeptember 5, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Genmab (GMAB)September 5, 2023 | markets.businessinsider.comEncouraging Data From Seagen/Genmab's Cervical Cancer Study - Tivdak Success Sets Stage For New IndicationsSeptember 24, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.September 5, 2023 | finance.yahoo.comSeagen's (SGEN) Late-Stage Cervical Cancer Study Meets GoalsSeptember 5, 2023 | finance.yahoo.comWhy Shares of Zai Lab Limited Were Jumping on TuesdaySeptember 4, 2023 | reuters.comGenmab, Seagen say Tivdak cervical cancer trial met overall survival endpointAugust 31, 2023 | msn.comDenmark stocks lower at close of trade; OMX Copenhagen 20 down 1.55%August 30, 2023 | seekingalpha.comGenmab Is Down To Attractive LevelsSeptember 24, 2023 | Chaikin Analytics (Ad)His system isolated NVIDIA - Here's His Next Buy.Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.August 15, 2023 | markets.businessinsider.comAnalyst Expectations for Genmab's FutureAugust 9, 2023 | markets.businessinsider.comGenmab (GMAB) Receives a Buy from Truist FinancialJuly 28, 2023 | finanznachrichten.deGenmab A/S: Genmab Updates 2023 Financial GuidanceJuly 28, 2023 | seekingalpha.comGenmab raises FY 2023 guidance on back of Darzalex salesJuly 24, 2023 | markets.businessinsider.com12 Analysts Have This to Say About GenmabJuly 21, 2023 | finance.yahoo.comGenmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)July 20, 2023 | finanznachrichten.deGenmab A/S: Genmab Announces Net Sales of DARZALEX (daratumumab) for Second Quarter of 2023July 20, 2023 | finance.yahoo.comGenmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2023July 17, 2023 | msn.comDenmark stocks higher at close of trade; OMX Copenhagen 20 up 0.46%July 14, 2023 | markets.businessinsider.comMorgan Stanley Keeps Their Sell Rating on Genmab (GMAB)July 7, 2023 | msn.comDenmark stocks lower at close of trade; OMX Copenhagen 20 down 0.41%June 29, 2023 | seekingalpha.comGenmab: Epkinly's Approval Not Big Enough Needle-Mover (Neutral)June 27, 2023 | marketwatch.comAbbVie, Genmab Need Further Follow Up on Trial for Follicular Lymphoma TreatmentJune 27, 2023 | tmcnet.comGenmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating EpcoritamabJune 27, 2023 | nasdaq.comAbbVie Announces Positive Results From Phase 1/2 Trial Of Epcoritamab In R/R Follicular LymphomaJune 21, 2023 | finanznachrichten.deNasdaq Copenhagen A/S: Genmab A/S - admittance to trading and official listing of new shares due to employee warrant exerciseJune 20, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: BioNTech SE (BNTX), Genmab (GMAB) and Immunocore Holdings (IMCR)June 12, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), Inspire Medical Systems (INSP) and Genmab (GMAB)See More Headlines Receive GMAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address GMAB Company Calendar Last Earnings8/03/2023Today9/23/2023Next Earnings (Estimated)11/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GMAB CUSIPN/A CIK1434265 Webwww.genmab.com Phone(457) 020-2728FaxN/AEmployees1,660Year Founded1999Price Target and Rating Average Stock Price Forecast$41.40 High Stock Price Forecast$54.00 Low Stock Price Forecast$23.00 Forecasted Upside/Downside+14.7%Consensus RatingHold Rating Score (0-4)2.27 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)$1.00 Trailing P/E Ratio36.08 Forward P/E Ratio35.37 P/E Growth2.17Net Income$781.91 million Net Margins28.78% Pretax Margin36.62% Return on Equity16.93% Return on Assets15.11% Debt Debt-to-Equity RatioN/A Current Ratio14.93 Quick Ratio14.90 Sales & Book Value Annual Sales$2.07 billion Price / Sales11.53 Cash Flow$1.25 per share Price / Cash Flow28.89 Book Value$5.89 per share Price / Book6.13Miscellaneous Outstanding Shares660,570,000Free Float650,398,000Market Cap$23.83 billion OptionableNot Optionable Beta0.94 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Jan G.J. van de Winkel Ph.D. (Age 62)Co-Founder, Pres & CEO Comp: $2.71MMr. Anthony Pagano (Age 45)Exec. VP & CFO Comp: $1.01MMr. Anthony Mancini (Age 52)Exec. VP & COO Comp: $1.1MMr. Martin Schultz (Age 47)Sr. Director of Clinical Operations & Non-Independent Director Comp: $72.04kDr. Judith V. Klimovsky M.D. (Age 65)Exec. VP & Chief Devel. Officer Comp: $1.14MDr. Tahamtan Ahmadi (Age 50)Exec. VP, Chief Medical Officer & Head of Experimental Medicines Comp: $1.08MDr. Mijke Zachariasse Ph.D. (Age 49)Sr. Director, Head of Antibody Research Materials & Non-Independent Director Comp: $144.08kMr. Takahiro Hamatani (Age 48)Sr. Director of Fin. Japan & Non-Independent Director Comp: $72.04kMr. Andrew CarlsenSr. Director, VP & Head of Investor RelationsMs. Birgitte Stephensen M.Sc. (Age 62)Exec. VP & Chief Legal Officer More ExecutivesKey CompetitorsHorizon Therapeutics PublicNASDAQ:HZNPAlnylam PharmaceuticalsNASDAQ:ALNYBeiGeneNASDAQ:BGNEViatrisNASDAQ:VTRSTeva Pharmaceutical IndustriesNYSE:TEVAView All CompetitorsInstitutional OwnershipArlington Capital Management Inc.Bought 898 shares on 8/24/2023Ownership: 0.006%Osaic Holdings Inc.Sold 698 shares on 8/21/2023Ownership: 0.004%Orion Portfolio Solutions LLCSold 1,527 shares on 8/17/2023Ownership: 0.003%Rockefeller Capital Management L.P.Sold 4,534 shares on 8/15/2023Ownership: 0.002%Captrust Financial AdvisorsSold 520 shares on 8/15/2023Ownership: 0.001%View All Institutional Transactions GMAB Stock - Frequently Asked Questions Should I buy or sell Genmab A/S stock right now? 15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Genmab A/S in the last twelve months. There are currently 2 sell ratings, 7 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GMAB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GMAB, but not buy additional shares or sell existing shares. View GMAB analyst ratings or view top-rated stocks. What is Genmab A/S's stock price forecast for 2023? 15 equities research analysts have issued 1-year price targets for Genmab A/S's stock. Their GMAB share price forecasts range from $23.00 to $54.00. On average, they predict the company's stock price to reach $41.40 in the next year. This suggests a possible upside of 14.7% from the stock's current price. View analysts price targets for GMAB or view top-rated stocks among Wall Street analysts. How have GMAB shares performed in 2023? Genmab A/S's stock was trading at $42.38 at the beginning of the year. Since then, GMAB stock has decreased by 14.9% and is now trading at $36.08. View the best growth stocks for 2023 here. Are investors shorting Genmab A/S? Genmab A/S saw a drop in short interest in August. As of August 31st, there was short interest totaling 2,890,000 shares, a drop of 16.2% from the August 15th total of 3,450,000 shares. Based on an average daily volume of 485,500 shares, the days-to-cover ratio is presently 6.0 days. View Genmab A/S's Short Interest. When is Genmab A/S's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023. View our GMAB earnings forecast. How were Genmab A/S's earnings last quarter? Genmab A/S (NASDAQ:GMAB) issued its quarterly earnings results on Thursday, August, 3rd. The company reported $0.30 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.31 by $0.01. The business earned $613.43 million during the quarter, compared to the consensus estimate of $618.77 million. Genmab A/S had a trailing twelve-month return on equity of 16.93% and a net margin of 28.78%. What ETFs hold Genmab A/S's stock? ETFs with the largest weight of Genmab A/S (NASDAQ:GMAB) stock in their portfolio include First Trust NYSE Arca Biotechnology Index Fund (FBT), iShares Biotechnology ETF (IBB), Goldman Sachs Future Health Care Equity ETF (GDOC), B.A.D. Etf (BAD), Range Cancer Therapeutics ETF (CNCR) and WisdomTree BioRevolution Fund (WDNA).ActivePassive International Equity ETF (APIE). What guidance has Genmab A/S issued on next quarter's earnings? Genmab A/S issued an update on its FY 2023 earnings guidance on Friday, July, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.27 billion-$2.41 billion, compared to the consensus revenue estimate of $2.38 billion. What other stocks do shareholders of Genmab A/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other Genmab A/S investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), CVS Health (CVS), Home Depot (HD), Intel (INTC), Pfizer (PFE), PayPal (PYPL), Verizon Communications (VZ) and Cisco Systems (CSCO). When did Genmab A/S IPO? (GMAB) raised $503 million in an IPO on Thursday, July 18th 2019. The company issued 27,800,000 shares at $18.11 per share. BofA Merrill Lynch, Morgan Stanley and Jefferies served as the underwriters for the IPO and Guggenheim Securities and RBC Capital Markets were co-managers. What is Genmab A/S's stock symbol? Genmab A/S trades on the NASDAQ under the ticker symbol "GMAB." Who are Genmab A/S's major shareholders? Genmab A/S's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Alliancebernstein L.P. (1.24%), BlackRock Inc. (0.79%), Capital International Investors (0.64%), Renaissance Technologies LLC (0.13%), Stifel Financial Corp (0.11%) and Royal Bank of Canada (0.11%). How do I buy shares of Genmab A/S? Shares of GMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Genmab A/S's stock price today? One share of GMAB stock can currently be purchased for approximately $36.08. How much money does Genmab A/S make? Genmab A/S (NASDAQ:GMAB) has a market capitalization of $23.83 billion and generates $2.07 billion in revenue each year. The company earns $781.91 million in net income (profit) each year or $1.00 on an earnings per share basis. How many employees does Genmab A/S have? The company employs 1,660 workers across the globe. How can I contact Genmab A/S? Genmab A/S's mailing address is Kalvebod Brygge 43, Copenhagen G7, 1560. The official website for the company is www.genmab.com. The company can be reached via phone at (457) 020-2728 or via email at acn@genmab.com. This page (NASDAQ:GMAB) was last updated on 9/24/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genmab A/S Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.